Genetics and epigenetics of liver cancer
Research output: Contribution to journal › Review › Research › peer-review
Standard
Genetics and epigenetics of liver cancer. / Ozen, Cigdem; Yildiz, Gokhan; Dagcan, Alper Tunga; Cevik, Dilek; Ors, Aysegul; Keles, Umur; Topel, Hande; Ozturk, Mehmet.
In: New Biotechnology, Vol. 30, No. 4, 25.05.2013, p. 381-4.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Genetics and epigenetics of liver cancer
AU - Ozen, Cigdem
AU - Yildiz, Gokhan
AU - Dagcan, Alper Tunga
AU - Cevik, Dilek
AU - Ors, Aysegul
AU - Keles, Umur
AU - Topel, Hande
AU - Ozturk, Mehmet
N1 - Copyright © 2013 Elsevier B.V. All rights reserved.
PY - 2013/5/25
Y1 - 2013/5/25
N2 - Hepatocellular carcinoma (HCC) represents a major form of primary liver cancer in adults. Chronic infections with hepatitis B (HBV) and C (HCV) viruses and alcohol abuse are the major factors leading to HCC. This deadly cancer affects more than 500,000 people worldwide and it is quite resistant to conventional chemo- and radiotherapy. Genetic and epigenetic studies on HCC may help to understand better its mechanisms and provide new tools for early diagnosis and therapy. Recent literature on whole genome analysis of HCC indicated a high number of mutated genes in addition to well-known genes such as TP53, CTNNB1, AXIN1 and CDKN2A, but their frequencies are much lower. Apart from CTNNB1 mutations, most of the other mutations appear to result in loss-of-function. Thus, HCC-associated mutations cannot be easily targeted for therapy. Epigenetic aberrations that appear to occur quite frequently may serve as new targets. Global DNA hypomethylation, promoter methylation, aberrant expression of non-coding RNAs and dysregulated expression of other epigenetic regulatory genes such as EZH2 are the best-known epigenetic abnormalities. Future research in this direction may help to identify novel biomarkers and therapeutic targets for HCC.
AB - Hepatocellular carcinoma (HCC) represents a major form of primary liver cancer in adults. Chronic infections with hepatitis B (HBV) and C (HCV) viruses and alcohol abuse are the major factors leading to HCC. This deadly cancer affects more than 500,000 people worldwide and it is quite resistant to conventional chemo- and radiotherapy. Genetic and epigenetic studies on HCC may help to understand better its mechanisms and provide new tools for early diagnosis and therapy. Recent literature on whole genome analysis of HCC indicated a high number of mutated genes in addition to well-known genes such as TP53, CTNNB1, AXIN1 and CDKN2A, but their frequencies are much lower. Apart from CTNNB1 mutations, most of the other mutations appear to result in loss-of-function. Thus, HCC-associated mutations cannot be easily targeted for therapy. Epigenetic aberrations that appear to occur quite frequently may serve as new targets. Global DNA hypomethylation, promoter methylation, aberrant expression of non-coding RNAs and dysregulated expression of other epigenetic regulatory genes such as EZH2 are the best-known epigenetic abnormalities. Future research in this direction may help to identify novel biomarkers and therapeutic targets for HCC.
KW - Carcinoma, Hepatocellular/genetics
KW - Epigenesis, Genetic
KW - Epigenomics
KW - Humans
KW - Liver Neoplasms/genetics
U2 - 10.1016/j.nbt.2013.01.007
DO - 10.1016/j.nbt.2013.01.007
M3 - Review
C2 - 23392071
VL - 30
SP - 381
EP - 384
JO - New Biotechnology
JF - New Biotechnology
SN - 1871-6784
IS - 4
ER -
ID: 389913877